The effect of oxcarbazepine in the treatment of agitation/aggression in dementia (OBAD) - An eight week prospective, randomized, double-blind, placebo-controlled, multicenter trial. A phase III study

Trial Profile

The effect of oxcarbazepine in the treatment of agitation/aggression in dementia (OBAD) - An eight week prospective, randomized, double-blind, placebo-controlled, multicenter trial. A phase III study

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2009

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Aggression; Agitation; Dementia
  • Focus Therapeutic Use
  • Acronyms OBAD
  • Most Recent Events

    • 01 Feb 2009 Results published in Dementia and Geriatric Cognitive Disorders.
    • 20 Mar 2007 Status changed from in progress to completed.
    • 18 Sep 2006 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top